1
|
Zambon A, Nguyen TA, Fourcade A, Segalen T, Saout K, Deruelle C, Joulin V, Tissot V, Doucet L, Fournier G, Valeri A. Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors. Prostate Cancer Prostatic Dis 2023:10.1038/s41391-023-00770-3. [PMID: 38114598 DOI: 10.1038/s41391-023-00770-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 11/16/2023] [Accepted: 11/24/2023] [Indexed: 12/21/2023]
Abstract
BACKGROUND Current prostate biopsy (PBx) protocol for prostate cancer (PCa) diagnosis is to perform systematic biopsies (SBx) combined with targeted biopsies (TBx) in case of positive MRI (i.e. PI-RADS ≥ 3). To assess the utility of performing SBx in combination with TBx, we determined the added value of SBx brought to the diagnosis of PCa according to their sextant location and MRI target characteristics. METHODS In our local prospectively collected database, we conducted a single-center retrospective study including all patients with a suspicion of PCa, who underwent transrectal ultrasound-guided (TRUS) prostate biopsies (PBx) with a prior MRI and a single lesion classified as PI-RADS ≥ 3. We have characterized the SBx according to their location on MRI: same sextant (S-SBx), adjacent sextant (A-SBx), ipsilateral side (I-SBx) and contralateral side (C-SBx). The added value of SBx and TBx was defined as any upgrading to significant PCa (csPCa) (ISUP ≥2). RESULTS 371 patients were included in the study. The added value of SBx was 10% overall. Regarding the lesion location and the SBx sextant, the added value of SBx was: 5.1% for S-SBx, 5.4% for A-SBx, 4.9% for I-SBx and 1.9% for C-SBx. The overall added value of SBx was 6.8% for PI-RADS 3 lesions, 14% for PI-RADS 4 lesions and 6.7% for PI-RADS 5 lesions (p = 0.063). The added value of SBx for contralateral side was 1.9% (2/103), 3.1% (5/163) and 0% (0/105) for PI-RADS 3, PI-RADS 4 and PI-RADS 5 lesions, respectively (p = 0,4). The added value of SBx was lower when the number of TBx was higher (OR 0.57; CI 95% 0.37-0.85; p = 0.007). CONCLUSIONS Our results suggest that the utility of performing SBx in the contralateral lobe toward the MRI lesion was very low, supporting that they might be avoided.
Collapse
Affiliation(s)
- A Zambon
- Urology Department, Brest University Hospital, Brest, France.
| | - T-A Nguyen
- Urology Department, Brest University Hospital, Brest, France
- LaTIM-UMR 1101, INSERM, EFS, Université de Bretagne Occidentale, Brest, France
| | - A Fourcade
- Urology Department, Brest University Hospital, Brest, France
| | - T Segalen
- Urology Department, Brest University Hospital, Brest, France
| | - K Saout
- Urology Department, Brest University Hospital, Brest, France
| | - C Deruelle
- Urology Department, Brest University Hospital, Brest, France
| | - V Joulin
- Urology Department, Brest University Hospital, Brest, France
| | - V Tissot
- Radiology Department, Brest University Hospital, Brest, France
| | - L Doucet
- Pathology Department, Brest University Hospital, Brest, France
| | - G Fournier
- Urology Department, Brest University Hospital, Brest, France
- LaTIM-UMR 1101, INSERM, EFS, Université de Bretagne Occidentale, Brest, France
- CeRePP, Paris, France
| | - A Valeri
- Urology Department, Brest University Hospital, Brest, France
- LaTIM-UMR 1101, INSERM, EFS, Université de Bretagne Occidentale, Brest, France
- CeRePP, Paris, France
| |
Collapse
|
2
|
Doucet L, Cailleteau A, Vaugier L, Gourmelon C, Bureau M, Salaud C, Roualdes V, Samarut E, Aumont M, Zenatri M, Loussouarn D, Quillien V, Bocquet F, Payen-Gay L, Joubert D, Prieur A, Robert M, Frenel JS. Association between post-operative hPG 80 (circulating progastrin) detectable level and worse prognosis in glioblastoma. ESMO Open 2023; 8:101626. [PMID: 37713930 PMCID: PMC10594012 DOI: 10.1016/j.esmoop.2023.101626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 07/06/2023] [Accepted: 08/02/2023] [Indexed: 09/17/2023] Open
Abstract
BACKGROUND Patients with glioblastomas have a dismal prognosis, and there is no circulating predictive or prognostic biomarker. Circulating progastrin, hPG80, is a tumor-promoting peptide present in the blood of patients with various cancers that has been shown to have prognostic value. We evaluated the prognostic value of plasma hPG80 in patients with isocitrate dehydrogenase-wild type glioblastoma after surgery. PATIENTS AND METHODS A multicentric retrospective study in glioblastoma patients treated with standard radio-chemotherapy was conducted. The hPG80 levels were measured in plasma EDTA samples collected after surgery with an ELISA DxPG80.lab kit (Biodena Care, Montpellier, France), which has a detection threshold of 1.2 pM. The relationship between post-operative hPG80 plasma levels, in combination with other known prognostic factors, and patients' progression-free survival (PFS) and overall survival (OS) was evaluated. RESULTS Sixty-nine patients were assessable. Plasma samples were collected after tumor biopsy (B), partial resection (PR), and complete resection (CR) for 22, 25, and 22 patients, respectively. At a median concentration of 5.37 pM (interquartile range 0.00-13.90 pM), hPG80 was detected in 48 (70%) patients (hPG80+). CR was associated with significant lower values of hPG80 levels: the median value was 0.7 versus 9.1 pM for PR (P = 0.02) and 8.3 pM for B (P = 0.004). The hPG80 detection rate was also significantly lower: 50% (CR) versus 72% (PR) versus 86% (B) (P = 0.005). The median follow-up was 39 months [22.4 months-not reached]. hPG80 post-operative detection was associated with numerically shorter PFS (6.4 versus 9.4 months, P = 0.13) and OS (14.5 versus 20.9 months, P = 0.11). In multivariate analysis, hPG80 was a prognostic factor for OS (P = 0.034). CONCLUSIONS Circulating hPG80 could serve as a new prognostic biomarker after surgery in patients with glioblastoma treated with radio-chemotherapy.
Collapse
Affiliation(s)
- L Doucet
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.
| | - A Cailleteau
- Department of Radiation Therapy, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - L Vaugier
- Department of Radiation Therapy, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - C Gourmelon
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - M Bureau
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - C Salaud
- Department of Neurosurgery, Centre Hospitalo-Universitaire, Nantes, France
| | - V Roualdes
- Department of Neurosurgery, Centre Hospitalo-Universitaire, Nantes, France
| | - E Samarut
- Department of Neurosurgery, Centre Hospitalo-Universitaire, Nantes, France
| | - M Aumont
- Department of Radiation Therapy, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - M Zenatri
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - D Loussouarn
- Department of Pathology, Centre Hospitalo-Universitaire, Nantes, France
| | - V Quillien
- Department of Biology, Centre Eugene Marquis, Rennes, France
| | - F Bocquet
- Data Factory & Analytics, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - L Payen-Gay
- Department of Biochemistry, Molecular Oncology and Transfer Unit, Cancer Institute of Hospices Civils De Lyon, Pierre Benite, France
| | | | | | - M Robert
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| | - J-S Frenel
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France
| |
Collapse
|
3
|
Payrard-Starck C, Fourcade A, An Nguyen T, Tissot V, Doucet L, Marolleau J, Lucas C, Fournier G, Valeri A. Direct comparison between Grade Group assessed on systematic and MRI/ultrasound fusion targeted biopsies correlated to the radical prostatectomy specimens in patients with prostate cancer. Prog Urol 2023; 33:265-271. [PMID: 36740508 DOI: 10.1016/j.purol.2023.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2022] [Revised: 10/02/2022] [Accepted: 01/16/2023] [Indexed: 02/06/2023]
Abstract
OBJECTIVES To compare the correlation of Gleason score (GS) and ISUP grade determined by prostate biopsies (PBx) and radical prostatectomy (RP) specimens according to the biopsy technique: ultrasound randomised (RBx) vs. MRI/ultrasound fusion targeted (TBx). MATERIALS AND METHODS Between March 2013 and June 2018, we retrospectively included patients who underwent RP for prostate cancer (PCa) histopathologically proven by RBx and/or TBx. All patients had a prebiopsy MRI by a single radiologist (using PI-RADS score), then transrectal RBx (12cores, blinded to MRI lesions) and TBx (2-4 cores/target) with elastic MRI/ultrasound fusion (UroStation™, Koelis, Grenoble, France). Histological findings were compared: PBx vs. RP. RESULTS One hundred and four patients underwent RP after RBx and/or TBx. ISUP concordance rate was better with the association RBx+TBx 49% (51/104) vs. 43.3% with TBx (P=0.07) and 43.3% with RBx (P=0.13). With RBx, 50% of the patients were downgraded (52/104) against 42.3% (44/104) with TBx (P=0.088). The association RBx+TBx significantly decreased the rate of downgrading of the ISUP score compared to the ISUP score of RP 35.6% (37/104) vs. RBx (50%, P=0.0001) and vs. TBx (42.3%, P=0.016). CONCLUSION In half of cases, the ISUP score was underestimated in RBx compared to RP specimens. Adding TBx to RBx significantly reduced downgrading. The combination of both biopsy techniques appeared to be the best protocol to get closer to ISUP score and GS of the RP specimens. LEVEL OF EVIDENCE C.
Collapse
Affiliation(s)
- C Payrard-Starck
- Urology Department, CHU Brest, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France.
| | - A Fourcade
- Urology Department, CHU Brest, Brest, France
| | - T An Nguyen
- Urology Department, CHU Brest, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France; LaTIM, Inserm, UMR 1101, CHU Brest, Brest, France
| | - V Tissot
- Radiology Department, CHU Brest, Brest, France
| | - L Doucet
- Pathology Department, CHU Brest, Brest, France
| | - J Marolleau
- Urology Department, CHU Brest, Brest, France
| | - C Lucas
- Urology Department, CHU Brest, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France
| | - G Fournier
- Urology Department, CHU Brest, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France; LaTIM, Inserm, UMR 1101, CHU Brest, Brest, France
| | - A Valeri
- Urology Department, CHU Brest, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France; LaTIM, Inserm, UMR 1101, CHU Brest, Brest, France
| |
Collapse
|
4
|
Zambon A, Nguyen T, Fourcade A, Saout K, Deruelle C, Joulin V, Tissot V, Doucet L, Fournier G, Valeri A. Interest of systematic prostatic biopsies in patients with a suspicious lesion on MRI: Analysis by sectors according to the target location. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00222-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
5
|
Marolleau J, Nguyen TA, Doucet L, Coste A, Schoentgen N, Rousseau B, Valeri A, Fournier G. [Morbidity of extended pelvic lymphadenectomy during robot-assisted laparoscopic prostatectomy for localized cancer prostate]. Prog Urol 2022; 32:1455-1461. [PMID: 36088200 DOI: 10.1016/j.purol.2022.07.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 07/02/2022] [Accepted: 07/18/2022] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To assess the morbidity specific of extended pelvic lymphadenectomy during robot-assisted laparoscopic radical prostatectomy in a 8 year retrospective study. MATERIAL We carried out a single-center, single-surgeon retrospective study on 342 consecutive patients who underwent a robot-assisted laparoscopic radical prostatectomy and extended pelvic lymphadenectomy, from July 2010 to March 2018. Postoperative complications were recorded up to 3 months after the operation. RESULTS Thirty (8.8%) patients had at least one complication related to lymphadenectomy including 1 vascular injury (0.3%), 7 injuries of the obturator nerve (2%), 5 venous thromboembolic complications (1.5%) including 4 pulmonary embolisms, 10 symptomatic lymphoceles (2.9%) and 8 lymphoedemas (2.3%). Of these complications, 13 were classified Clavien 1 (43.3%), 8 Clavien 2 (26.7%), 7 Clavien 3a (23.3%) and 2 Clavien 3b (6.7%). In univariate analysis a high age (P=0.04), high BMI (P<0.01) and pT stage (P=0.02) were significantly associated with complication whereas in multivariate analysis, only age (P=0.02) and BMI (P<0.01) lived were. In univariate analysis high BMI (P=0.04) and lymph node involvement (P=0.04) were associated with lymphatic complication. We did not find any other specific risk factor for the other complications. CONCLUSION With 8.8% of overall complications related to lymphadenectomy and 5% of complication classified Clavien grade 2 or higher, extended pelvic lymphadenectomy was not very morbid. Age and BMI were risk factors for a overall complication. BMI and lymph node involvement were risk factors for lymphatic complications. LEVEL OF PROOF 4.
Collapse
Affiliation(s)
| | - T A Nguyen
- Service d'urologie, CHU, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Bretagne Occidentale, Brest, France; LaTIM, Inserm, UMR 1101, Université de Bretagne Occidentale, Brest, France
| | - L Doucet
- Laboratoire d'anatomo-pathologie, CHU, Brest, France
| | - A Coste
- LaTIM, Inserm, UMR 1101, Université de Bretagne Occidentale, Brest, France; Service de médecine infectieuse et tropicale, CHU, Brest, France
| | | | | | - A Valeri
- Service d'urologie, CHU, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Bretagne Occidentale, Brest, France; LaTIM, Inserm, UMR 1101, Université de Bretagne Occidentale, Brest, France; CeRePP, Paris, France
| | - G Fournier
- Service d'urologie, CHU, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Bretagne Occidentale, Brest, France; LaTIM, Inserm, UMR 1101, Université de Bretagne Occidentale, Brest, France; CeRePP, Paris, France
| |
Collapse
|
6
|
Nguyen T, Tixier F, Tissot V, Fourcade A, Saout K, Zambon A, Payrard C, Deruelle C, Joulin V, Doucet L, Visvikis D, Fournier G, Valeri A. Radiomic-based model for prediction of clinically significant prostate cancer in patients with a PI-RADS 3 MRI lesion. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00360-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
7
|
Saout K, Zambon A, Nguyen T, Lucas C, Payrard-Starck C, Segalen T, Tissot V, Doucet L, Marolleau J, Deruelle C, Joulin V, Fourcade A, Fournier G, Valeri A. Impact of multiparametric MRI and PSA density on the initial indication or the maintaining in active surveillance during follow-up in low-risk prostate cancer. Clin Genitourin Cancer 2022; 20:e244-e252. [DOI: 10.1016/j.clgc.2022.01.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Revised: 01/12/2022] [Accepted: 01/17/2022] [Indexed: 11/25/2022]
|
8
|
Nguyen T, Cussenot O, Fiard G, Fourcade A, Tissot V, Doucet L, Fournier G, Valeri A. Impact de l’âge et de la densité du PSA sur la détection du cancer de prostate chez les patients avec IRM prostatique négative. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Doucet L, Hoflack S, Van Slambrouck L, Lormans P. The use of methylprednisolone in patients with Coronavirus disease 2019 (COVID-19) requiring intensive care hospitalization: a longitudinal observational study. Acta Anaest Belg 2021. [DOI: 10.56126/72.3.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The use of methylprednisolone in patients with Coronavirus disease 2019 (COVID-19) requiring intensive care hospitalization: a longitudinal observational study.
Background : For a long time, the use of corticosteroids in critically ill patients with coronavirus disease 2019 (COVID-19) has been a controversial treatment. How- ever, given the conflicting evidence on this topic, we studied the effects of methylprednisolone on critically ill patients and - share here our experience on laboratory findings and the Pa02/FiO2 ratio (ratio of partial oxygen concentration on arterial blood gas sample to fraction of inspired oxygen).
Methods : In a population of 68 patients hospitalized in the intensive care unit due because of COVID-19 infection, 28 patients with severe respiratory failure received methylprednisolone on a fixed 12-day regimen (125 mg IV for 2 days, followed by 2x0.5 mg/kg IV twice daily for 5 days, and then a decreasing regimen for 4 days until discontinuation). After day 5 and day 10, we analyzed the levels of CRP (C-reactive protein), lymphocytosis, D-dimer, LDH (lactate dehydrogenase) and PaO 2 /FiO 2 ratio of our patients.
Results : We observed a significant decrease in median CRP levels between day 0 (start of methylprednisolone treatment) and day 5 (p=0.001), and between day 0 and day 10 (p=0.005). No decrease was seen between day 5 and 10 (p=0.352). The same increase in PaO 2 /FiO 2 was recorded between day 0 and day 5 (p=0.009), and between 0 and day 10 (p=0.019). For D-dimer, only a significant difference was found between day 0 and day 10 (p=0.018). No significant difference could be observed for lymphocytosis and LDH levels between the beginning of the treatment and day 5 or day 10.
Conclusion : There is a strong and sustained significant decrease in CRP levels and a tilt in the PaO2/FiO2 ratio after starting methylprednisolone. A slower, but also significant decrease was found for D-dimer. Further research and control group analyses are needed to confirm that this effect is due to corticostreoid treatment. However, this indicates that methylprednisolone may play a very important role in the treatment of the severely ill COVID-19 patients requiring ICU admission.
Collapse
|
10
|
Piroth M, Bourgin C, Loaec C, Classe J, Doucet L, Heymann M, Kerdraon O, Peuvrel L, Saint Jean M. Analyse en vie réelle de la technique du ganglion sentinelle dans la prise en charge du mélanome primitif dans un centre d’onco-dermatologie. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Saout K, Zambon A, N’Guyen T, Lucas C, Payrard-Starck C, Marolleau J, Segalen T, Tissot V, Doucet L, Deruelle C, Joulin V, Fourcade A, Fournier G, Valeri A. Impact de la densité du PSA et de l’IRM multiparamétrique dans l’indication à une surveillance active d’un adénocarcinome prostatique à faible risque. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Rafii H, Frère C, Benzidia I, Crichi B, Andre T, Assenat E, Bournet B, Carpentier A, Connault J, Doucet L, Durant C, Emmerich J, Gris JC, Hij A, Le Hello C, Madelaine I, Messas E, Ndour A, Villiers S, Marjanovic Z, Ait Abdallah N, Yannoutsos A, Farge D. Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). J Med Vasc 2020; 45:28-40. [PMID: 32057323 DOI: 10.1016/j.jdmv.2019.12.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/01/2019] [Accepted: 12/06/2019] [Indexed: 06/10/2023]
Abstract
Venous thromboembolism (VTE) is a common disease complication in cancer patients and the second cause of death after cancer progression. VTE management and prophylaxis are critical in cancer patients, but effective therapy can be challenging because these patients are at higher risk of VTE recurrence and bleeding under anticoagulant treatment. Numerous published studies report inconsistent implementation of existing evidence-based clinical practice guidelines (CPG), including underutilization of thromboprophylaxis, and wide variability in clinical practice patterns across different countries and various practitioners. This review aims to summarize the 2019 ITAC-CME evidence-based CPGs for treatment and prophylaxis of cancer-related VTE, which include recommendations on the use of direct oral anticoagulants specifically in cancer patients. The guidelines underscore the gravity of developing VTE in cancer and recommend the best approaches for treating and preventing cancer-associated VTE, while minimizing unnecessary or over-treatment. Greater adherence to the 2019 ITAC guidelines could substantially decrease the burden of VTE and improve survival of cancer patients.
Collapse
Affiliation(s)
- H Rafii
- Eurocord, Équipe 3 EA3518, hôpital Saint-Louis, Université de Paris, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - C Frère
- Inserm UMRS_1166, Department of Haematology, hôpital Pitié-Salpêtrière, Université de Paris, Sorbonne Paris-Cité, AP-HP, Paris, France
| | - I Benzidia
- Autoimmune and vascular disease unit, hôpital Saint-Louis, Internal Medicine (UF04), Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, EA3518, AP-HP, Sorbonne Paris-Cité, Paris, France
| | - B Crichi
- Autoimmune and vascular disease unit, hôpital Saint-Louis, Internal Medicine (UF04), Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, EA3518, AP-HP, Sorbonne Paris-Cité, Paris, France
| | - T Andre
- Hôpital Saint-Antoine, AP-HP, Paris, France
| | - E Assenat
- Montpellier school of Medicine, Saint-Eloi University Hospital, Montpellier, France
| | - B Bournet
- Hôpital Rangueil, CHU de Toulouse, Toulouse, France
| | | | | | - L Doucet
- Hôpital Saint-Louis, AP-HP, Paris, France
| | | | | | | | - A Hij
- Autoimmune and vascular disease unit, hôpital Saint-Louis, Internal Medicine (UF04), Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, EA3518, AP-HP, Sorbonne Paris-Cité, Paris, France
| | - C Le Hello
- CHU Saint-Étienne, Saint-Étienne, France
| | | | - E Messas
- Hôpital Européen Georges-Pompidou, AP-HP, Paris, France
| | - A Ndour
- Hôpital Saint-Louis, AP-HP, Paris, France
| | - S Villiers
- Hôpital Saint-Louis, AP-HP, Paris, France
| | | | - N Ait Abdallah
- Autoimmune and vascular disease unit, hôpital Saint-Louis, Internal Medicine (UF04), Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, EA3518, AP-HP, Sorbonne Paris-Cité, Paris, France
| | | | - D Farge
- Internal Medicine (UF04), Équipe 3 EA 3518, Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, AP-HP, Sorbonne Paris-Cité, Paris, France; Department of Medicine, McGill University, Montreal, QC, Canada
| |
Collapse
|
13
|
Perrouin-Verbe MA, Schoentgen N, Talagas M, Garlantezec R, Uguen A, Doucet L, Rosec S, Marcorelles P, Potier-Cartereau M, Vandier C, Ferec C, Fromont G, Fournier G, Valeri A, Mignen O. Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy. Prostate 2019; 79:1793-1804. [PMID: 31475744 DOI: 10.1002/pros.23904] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2019] [Accepted: 08/16/2019] [Indexed: 12/24/2022]
Abstract
BACKGROUND Several studies had suggested the potential role of calcium signaling in prostate cancer (PCa) prognosis and agressiveness. We aimed to investigate selected proteins contributing to calcium (Ca2+ ) signaling, (Orai, stromal interaction molecule (STIM), and transient receptor potential (TRP) channels) and involved in cancer hallmarks, as independent predictors of systemic recurrence after radical prostatectomy (RP). METHODS A case-control study including 112 patients with clinically localized PCa treated by RP between 2002 and 2009 and with at least 6-years' follow-up. Patients were divided into two groups according to the absence or presence of systemic recurrence. Expression levels of 10 proteins involved in Ca2+ signaling (TRPC1, TRPC4, TRPV5, TRPV6, TRPM8, STIM1, STIM2, Orai1, Orai2, and Orai3), were assessed by immunohistochemistry using tissue microarrays (TMAs) constructed from paraffin-embedded PCa specimens. The level of expression of the various transcripts in PCa was assessed using quantitative polymerase chain reaction (qPCR) analysis. RNA samples for qPCR were obtained from fresh frozen tissue samples of PCa after laser capture microdissection on RP specimens. Relative gene expression was analyzed using the 2-▵▵Ct method. RESULTS Multivariate analysis showed that increased expression of TRPC1, TRPC4, TRPV5, TRPV6, TRPM8, and Orai2 was significantly associated with a lower risk of systemic recurrence after RP, independently of the prostate-specific antigen (PSA) level, percentage of positive biopsies, and surgical margin (SM) status (P = .007, P = .01, P < .001, P = .0065, P = .007, and P = .01, respectively). For TRPC4, TRPV5, and TRPV6, this association was also independent of Gleason score and pT stage. Moreover, overexpression of TRPV6 and Orai2 was significantly associated with longer time to recurrence after RP (P = .048 and .023, respectively). Overexpression of TRPC4, TRPV5, TRPV6, and Orai2 transcripts was observed in group R- (3.71-, 5.7-, 1.14-, and 2.65-fold increase, respectively). CONCLUSIONS This is the first study to suggest the independent prognostic value of certain proteins involved in Ca2+ influx in systemic recurrence after RP: overexpression of TRPC1, TRPC4, TRPV5, TRPV6, TRPM8, and Orai2 is associated with a lower risk of systemic recurrence. TRPC4, TRPV5, and TRPV6 appear to be particularly interesting, as they are independent of the five commonly used predictive factors, that is, PSA, percentage of positive biopsies, SM status, Gleason score, and pT stage.
Collapse
Affiliation(s)
- M A Perrouin-Verbe
- Department of Urology, CHRU-Université de Brest, Brest, France
- INSERM UMR1078, Université de Bretagne Occidentale, Brest, France
- Department of Urology, CHU-Université de Nantes, Nantes, France
| | - N Schoentgen
- Department of Urology, CHRU-Université de Brest, Brest, France
- INSERM UMR1078, Université de Bretagne Occidentale, Brest, France
| | - M Talagas
- Department of Pathology, CHRU-Université de Brest, Brest, France
- EA 4685 - LIEN, Université de Bretagne Occidentale, Brest, France
| | - R Garlantezec
- INSERM UMR1085-IRSET, Université Rennes 1, Rennes, France
| | - A Uguen
- Department of Pathology, CHRU-Université de Brest, Brest, France
| | - L Doucet
- Department of Pathology, CHRU-Université de Brest, Brest, France
| | - S Rosec
- INSERM UMR1412, Centre d'Investigation Clinique, CHRU-Université de Brest, Brest, France
| | - P Marcorelles
- Department of Pathology, CHRU-Université de Brest, Brest, France
| | | | - C Vandier
- INSERM UMR1069, Université François Rabelais, Tours, France
| | - C Ferec
- INSERM UMR1078, Université de Bretagne Occidentale, Brest, France
| | - G Fromont
- INSERM UMR1069, Université François Rabelais, Tours, France
- Department of Pathology, CHRU-Université de Tours, Tours, France
| | - G Fournier
- Department of Urology, CHRU-Université de Brest, Brest, France
| | - A Valeri
- Department of Urology, CHRU-Université de Brest, Brest, France
| | - O Mignen
- INSERM UMR1078, Université de Bretagne Occidentale, Brest, France
- INSERM UMR1227, Université de Bretagne Occidentale, Brest, France
| |
Collapse
|
14
|
Nguyen T, Fourcade A, Payrard-Starck C, Tissot V, Marolleau J, Doucet L, Lucas C, Deruelle C, Joulin V, Fournier G, Valeri A. Faut-il encore biopsier les patients avec IRM prostatique normale ? Sur la piste de facteurs prédictifs de cancer prostatique. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Borcoman E, Lemiale V, Dupont A, Mariotte E, Pichereau C, Doucet L, Joseph A, Chermak A, Valade S, Resche-Rigon M, Azoulay E. Survival trends in critically ill oncology patients: Impact of patient’s eligibility to post-ICU chemotherapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz265.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Bourbonne V, Vallieres M, Lucia F, Doucet L, Visvikis D, Tissot V, Cuvelier G, Hue S, Prigent L, Bertrand N, Staroz F, Pradier O, Hatt M, Schick U. Validation of an MRI-Derived Radiomics Model to Guide Patients Selection for Adjuvant Radiotherapy after Prostatectomy for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Reverte M, Etienne M, Fouchard M, Doucet L, Brenaut E, Misery L. Occurrence of Henoch-Schönlein purpura in a patient treated with secukinumab. J Eur Acad Dermatol Venereol 2019; 33:e455-e457. [PMID: 31282012 DOI: 10.1111/jdv.15776] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- M Reverte
- Department of Dermatology, University Hospital, Brest, France
| | - M Etienne
- Department of Dermatology, University Hospital, Brest, France.,Univ Brest, LIEN, Brest, France
| | - M Fouchard
- Department of Dermatology, University Hospital, Brest, France.,Univ Brest, LIEN, Brest, France
| | - L Doucet
- Department of Pathology, University Hospital, Brest, France
| | - E Brenaut
- Department of Dermatology, University Hospital, Brest, France.,Univ Brest, LIEN, Brest, France
| | - L Misery
- Department of Dermatology, University Hospital, Brest, France.,Univ Brest, LIEN, Brest, France
| |
Collapse
|
18
|
Chelabi S, Mignard X, Lacave R, Monnet I, Ollier M, Brosseau S, Theou-Anton N, Massiani M, Doucet L, De Cremoux P, Friard S, Duchemann B, Fabre E, Blons H, Giroux-Leprieur E, Azarian R, Cadranel J, Wislez M. Insertion exon 20 de l’EGFR dans les adénocarcinomes pulmonaires métastatiques : réponse au traitement et survie. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
19
|
Domblides C, Monnet I, Mazières J, Barlési F, Gounant V, Baldacci S, Mennecier B, Toffart A, Audigier-Valette C, Doucet L, Giroux-Leprieur E, Guisier F, Ricordel C, Molinier O, Pérol M, Pichon E, Robinet G, Templement-Grangerat D, Ruppert A, Rabbe N, Antoine M, Wislez M. Efficacité des inhibiteurs de checkpoint immunitaire dans le carcinome sarcomatoïde du poumon : données issues d’une cohorte française multicentrique. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
20
|
Lemasson J, Baroudjian B, Doucet L, Vitaux H, Herms F, Carpentier A, Lebbé C, Gounant V, Hautefort C, Delyon J. Toxicité audiovestibulaire des immunothérapies : première série de 4 cas. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
21
|
Campedel L, Assoun S, Bécourt S, Nguyen O, Ledoux F, Doucet L, Espié M, Teixeira L. Toxicités sévères des immunothérapies du cancer. Méd Intensive Réa 2018. [DOI: 10.3166/rea-2018-0070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
L’immunothérapie représente une avancée récente et importante en cancérologie. Les inhibiteurs de checkpoints immunitaires, ciblant les protéines PD-1, PD-L1 et CTLA-4, sont les thérapies les plus prometteuses et sont utilisés dans la prise en charge de plusieurs cancers. Les toxicités associées à ces traitements sont généralement moins fréquentes et moins graves que celles associées aux chimiothérapies et à la plupart des thérapies ciblées. Cependant, il existe un certain nombre de toxicités spécifiques de ce type de traitement, qui peuvent parfois être sévères et dont les plus fréquentes sont les toxicités pulmonaire, digestive, endocrinienne et cutanée. Dans cette mise au point, nous reviendrons sur la fréquence, le mécanisme et les principes de traitement des différentes toxicités sévères associées à l’immunothérapie.
Collapse
|
22
|
Domblides C, Monnet I, Mazieres J, Barlesi F, Gounant V, Baldacci S, Mennecier B, Toffart A, Audigier Valette C, Doucet L, Giroux-Leprieur E, Guisier F, Molinier O, Perol M, Pichon E, Robinet G, Templement Grangerat D, Ruppert AM, Wislez M. Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Medioni J, Brizard M, Teixeira L, Doucet L, Ghrieb Z, Angelergues A, Oudard S, Culine S, Adotevi O, Laheurte C, Dragon-Durey MA, Laurent-Puig P, Kiladjian JJ, Doppler V, Souttou B, Wain-Hobson S, Defrance R, Huet T, Langlade-Demoyen P. Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy279.403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Gobert A, Veyri M, Lavolé A, Montaudié H, Cloarec N, Doucet L, Gounant V, Massiani MA, Helissey C, Bregigeon S, Chouaid C, Poulet CH, Dewolf M, Kerjouan M, Beaucaire-Danel S, Brosseau S, Le Garff G, Garrait V, Marcelin AG, Spano JP. Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.051] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M, Irani J, Leroy X, Villers A, Fournier G, Doucet L, Boyault S, Brureau L, Multigner L, Diedhiou A, Roupret M, Compérat E, Blanchet P, de Reyniès A, Cussenot O. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol 2018; 29:1814-1821. [DOI: 10.1093/annonc/mdy224] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
|
26
|
Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Zalcman G, Jouveshomme S, Wislez M, Tredaniel J, Cadranel J. Efficacité du nivolumab (Nivo) et du traitement reçu après progression sous Nivo chez les patients atteints de cancer bronchique non à petites cellules (CBNPC) de stade avancé. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Callerot P, Valeri A, Fournier G, Moineau M, Cussenot O, Doucet L, Cancel-tassin G, Cormier L. Dépistage du cancer de la prostate dans les familles à risque. Le nombre d’apparentés atteints et l’âge précoce de diagnostic dans la famille augmentent le risque de CaP. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
28
|
Payrard C, Fourcade A, Tissot V, Valéri A, Fournier G, Doucet L. Concordance du score de Gleason entre biopsies prostatiques et anatomopathologie des pièces de prostatectomie radicale : augmentation de la précision grâce aux biopsies ciblées avec fusion écho/IRM ? Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
29
|
Butté Y, Hanrotel-Saliou C, Doucet L, Le Meur Y. Pronostic rénal des glomérulonéphrites associées aux anticorps anti-cytoplasme des polynucléaires neutrophiles (ANCA) selon la nouvelle classification histologique. Étude rétrospective d’une cohorte de 45 patients brestois. Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Fourcade A, Payrard C, Tissot V, Callerot P, Serey-Eiffel S, Demany N, Perrouin-Verbe M, Doucet L, Deruelle C, Joulin V, Fournier G, Valéri A. Intérêt de l’IRM prostatique et du score PIRADS dans la détection et l’évaluation des cancers de prostate avant biopsie prostatique. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
31
|
Fourcade A, Payrard C, Tissot V, Serey-Eiffel S, Callerot P, Demany N, Perrouin-verbe M, Doucet L, Deruelle C, Joulin V, Fournier G, Valéri A. Réévaluation des patients en surveillance active par des biopsies ciblées avec fusion élastique écho/IRM : vers une amélioration de la sélection des patients. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Fourcade A, Payrard C, Tissot V, Callerot P, Serey-eiffel S, Doucet L, Deruelle C, Joulin V, Fournier G, Valéri A. Vers l’amélioration de la détection des cancers prostatiques significatifs : protocole associant biopsies systématisées et biopsies ciblées avec fusion élastique écho/IRM. Prog Urol 2016. [DOI: 10.1016/j.purol.2016.07.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Guida A, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Porcu L, de Braud F, Porta C, Escudier B, Procopio G. Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
|
35
|
Le Meur Y, Aulagnon F, Bertrand D, Heng AE, Lavaud S, Caillard S, Longuet H, Sberro-Soussan R, Doucet L, Grall A, Legendre C. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors. Am J Transplant 2016; 16:2181-6. [PMID: 26718625 DOI: 10.1111/ajt.13698] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Revised: 12/14/2015] [Accepted: 12/12/2015] [Indexed: 01/25/2023]
Abstract
Transplant recipients receiving a kidney from an extended-criteria donor (ECD) are exposed to calcineurin inhibitor (CNI) nephrotoxicity, as demonstrated by severe delayed graft function and/or a low GFR. Belatacept is a nonnephrotoxic drug that is indicated as an alternative to CNIs. We reported 25 cases of conversion from a CNI to belatacept due to CNI intolerance within the first 6 mo after transplantation. The mean age of the recipients was 59 years, and 24 of 25 patients received ECD kidneys. At the date of the medication switch, 12 of 25 patients displayed a calculated GFR (cGFR) <15 mL/min, six patients remained on dialysis, and the biopsies showed evidence of acute tubular damage associated with severe vascular or tubulointerstitial chronic lesions. Three patients did not recover renal function, and three patients died during the follow-up period. Among the remaining patients, renal function improved: The cGFR was 18.28 ± 12.3 mL/min before the medication switch compared with 34.9 ± 14.5 mL/min at 1 year after conversion to belatacept (p = 0.002). Tolerance of and compliance with belatacept were good, and only one patient experienced acute rejection. Belatacept is an effective therapy that preserves renal function in kidney transplant patients who are intolerant of CNIs.
Collapse
Affiliation(s)
- Y Le Meur
- Department of Nephrology and Transplantation, University Hospital La Cavale Blanche, European University of Brittany, Brest, France
| | - F Aulagnon
- Department of Renal Transplantation, Necker-Enfants Malades University Hospital, AP-HP, Paris, France
| | - D Bertrand
- Department of Nephrology, University Hospital, Rouen, France
| | - A E Heng
- Department of Nephrology, University Hospital, Clermont-Ferrand, France
| | - S Lavaud
- Department of Nephrology and Transplantation, University Hospital, Reims, France
| | - S Caillard
- Department of Nephrology and Renal Transplantation, Hospices Civils, Strasbourg, France
| | - H Longuet
- Department of Nephrology and Clinical Immunology-EA4245, Bretonneau Hospital, University Hospital, Tours, France
| | - R Sberro-Soussan
- Department of Renal Transplantation, Necker-Enfants Malades University Hospital, AP-HP, Paris, France
| | - L Doucet
- Department of Anatomy and Pathology, University Hospital, Brest, France
| | - A Grall
- Department of Nephrology and Transplantation, University Hospital La Cavale Blanche, European University of Brittany, Brest, France
| | - C Legendre
- Department of Renal Transplantation, Necker-Enfants Malades University Hospital, AP-HP, Paris, France
| |
Collapse
|
36
|
Fourcade A, Perrouin-Verbe M, Tissot V, Callerot P, Serey-Eiffel S, Cuvelier G, Coquet J, Doucet L, Delage F, Thoulouzan M, Fournier G, Valéri A. [Not Available]. Prog Urol 2015; 25:832. [PMID: 26544424 DOI: 10.1016/j.purol.2015.08.230] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
37
|
Perrouin-verbe M, Mignen O, Doucet L, Talagas M, Rosec S, Fournier G, Valeri A. Remodelage de la signalisation calcique dans la tumeur prostatique : signature moléculaire de la récidive du cancer de prostate après chirurgie ? Prog Urol 2015; 25:839. [DOI: 10.1016/j.purol.2015.08.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Grassi P, Doucet L, Grunwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Giglione P, Santoni M, Verzoni E, Derosa L, Studentova H, Pacifici M, Maggi C, de Braud F, Porta C, Escudier B, Procopio G. Outcome of patients with pancreatic metastases from renal cell carcinoma: when the site matters. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv341.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Lefèvre E, Péraldi MN, Galmiche-Rolland L, Doucet L, Desbuissons G, Audard V, Delahousse M, Durrbach A, Karras A, Rondeau E, Snanoudj R, Salomon R, Mahr A. OP0232 Outcomes Following Renal Transplantation (RTX) in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV): An Analysis of 46 Patients. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Terrisse S, Doucet L, Pouessel D, Gauthier H, le Maignan C, Teixeira L, Pfister C, Culine S. Quelle chimiothérapie périopératoire pour les tumeurs de vessie infiltrant le muscle ? ONCOLOGIE 2015. [DOI: 10.1007/s10269-015-2510-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
41
|
Rousseau B, Doucet L, Perrouin Verbe MA, Papin G, Erauso A, Joulin V, Deruelle C, Valeri A, Fournier G. Comparaison de la morbidité entre curage étendu et curage limité au cours de la prostatectomie radicale laparoscopique. Prog Urol 2014; 24:114-20. [DOI: 10.1016/j.purol.2013.07.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2013] [Revised: 07/25/2013] [Accepted: 07/29/2013] [Indexed: 11/29/2022]
|
42
|
Rousseau B, Perrouin-Verbe M, Papin G, Thoulouzan M, Joulin V, Deruelle C, Doucet L, Valéri A, Fournier G. Curage ganglionnaire étendu dans le cancer de prostate : complications lymphatiques en fonction des limites anatomiques du curage. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
43
|
Erauso A, Perrouin-Verbe MA, Papin G, Volant A, Doucet L, Joulin V, Deruelle C, Rousseau B, Valeri A, Fournier G. [Urinary continence following laparoscopic radical prostatectomy: qualitative analysis]. Prog Urol 2012; 22:945-53. [PMID: 23102017 DOI: 10.1016/j.purol.2012.07.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2012] [Revised: 07/06/2012] [Accepted: 07/11/2012] [Indexed: 10/27/2022]
Abstract
PURPOSE The main purpose of this study was to report urinary continence after laparoscopic radical prostatectomy (LRP) for localised prostate cancer and the return to baseline rate for urinary continence. The minor purpose was to determine the risk factors, which influence return to baseline urinary continence after radical prostatectomy. METHODS Prospective evaluation of urinary continence with self-administered questionnaire in 300 consecutive LRP for localized prostate cancer. RESULTS After LRP, at 3, 6 and 12 months, respectively 12.5%, 23% and 33.7% of patients recover baseline urinary continence. Fifty-four percent, 72.3% and 78.4% of patients did not wear pads 3, 6 and 12 months after LRP. In patients without pad, 43 % recovered baseline continence one year after radical prostatectomy. In univariate analysis, age older than 60 years (P=0.003, P=0.003, P=0.02, 3, 6 and 12 months after LRP) and no sparing of neurovascular bundles (P=0.01, P=0.08 at 3 and 6 months after LRP) were risks factors of urinary incontinence. In multivariate analysis, only age older than 60 years (P=0.018, P=0.01 and P=0.01 at 3, 6 and 12 months after LRP) was a risk factor of urinary incontinence. CONCLUSION One year after LRP, 66.3% of patients had urinary incontinence according to our evaluation using stringent criteria, i.e. return to baseline continence status. However, only 21.6% of patients wore pads and less than 2% wore more than two pads per day.
Collapse
Affiliation(s)
- A Erauso
- Service d'urologie, hôpital de la Cavale Blanche, CHRU de Brest, Brest, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Kersale A, Wehbe B, Castella N, Brun D, Doucet L, Siohan P, Noël LH. Nécrose tubulaire aiguë hémorragique à la fluindione : premier cas prouvé histologiquement. Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
45
|
Talagas M, Fournier G, Garlantezec R, Gobin E, Doucet L, Volant A. Valeur pronostique de l’expression de VEGF, VEGFR-1, VEGFR-2, neuropiline 1 ET HIF-1α dans le cancer de la prostate cliniquement localisé. Ann Pathol 2011. [DOI: 10.1016/j.annpat.2011.09.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
46
|
Diallo M, Siohan P, Wehbé B, Doucet L, Jouquan J. Guérison prouvée histologiquement d’une glomérulopathie membranoproliférative de type 1 par Rituximab. Nephrol Ther 2011. [DOI: 10.1016/j.nephro.2011.07.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Emile J, Brahimi S, Coindre J, Blay J, Aegerter P, Scoazec J, Viennet G, Bouche O, Doucet L, Wacrenier A. Prognostic value of the most frequent mutations in GIST: Results of the French population-based prospective study MolecGIST. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Rousseau B, Kerfant N, Erauso A, Doucet L, Leloir M, Deruelle C, Joulin V, Valeri A, Fournier G. POS-03.116: Comparison between limited versus extended laparoscopic lymphadenectomy in localized prostate cancer: morbidity and efficiency. Urology 2007. [DOI: 10.1016/j.urology.2007.06.662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
49
|
|
50
|
Abstract
Several studies have demonstrated that intravenous administration of DNA complexed with cationic lipid vectors induces the production of large quantities of proinflammatory cytokines. In this study we confirm these observations, using cationic lipid DOTAP and cationic phospholipid compounds. Moreover, we demonstrate that although intravenous administration of lipid-DNA complexes does not induce toxic effects in the lung, high transgene expression in lung correlates with histopathological lesions in liver, this fact being documented by high transaminase levels in serum of treated mice. We examine the contribution of various components of the lipoplexes in this observed liver toxicity, as well as in the increasing level of transaminases, and more particularly the role of nonmethylated CpG sequences of plasmid DNA. We show that blood samples from animals treated either with cationic lipid alone, or with cationic lipid complexed with methylated plasmid DNA, contain low levels of transaminases. The significant decrease in transaminase levels after injection of cationic lipid-methylated pDNA complexes leads us to believe that nonmethylated CpG sequences could play a major role in this hepatoxicity. Similar results were observed when using a vector that did not encode a transgene, demonstrating that the expression of luciferase in lung was not responsible for this liver toxicity. All these observations suggest that significant work should be devoted to understand more clearly the mechanism of cationic lipid-DNA complex toxicity, and to overcome the problems subsequent to administration of non-methylated CpG sequences of plasmid DNA.
Collapse
Affiliation(s)
- S Loisel
- EPI-EMI 0115, CHU, UBO, Brest, France
| | | | | | | | | |
Collapse
|